HRP20161566T1 - Terapijski agensi za reguliranje serumskog fosfora - Google Patents

Terapijski agensi za reguliranje serumskog fosfora Download PDF

Info

Publication number
HRP20161566T1
HRP20161566T1 HRP20161566TT HRP20161566T HRP20161566T1 HR P20161566 T1 HRP20161566 T1 HR P20161566T1 HR P20161566T T HRP20161566T T HR P20161566TT HR P20161566 T HRP20161566 T HR P20161566T HR P20161566 T1 HRP20161566 T1 HR P20161566T1
Authority
HR
Croatia
Prior art keywords
composition
patient
hemodialysis
use according
serum phosphorus
Prior art date
Application number
HRP20161566TT
Other languages
English (en)
Croatian (hr)
Inventor
Felix Karim
Gregory Bell
Original Assignee
Kai Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kai Pharmaceuticals, Inc. filed Critical Kai Pharmaceuticals, Inc.
Publication of HRP20161566T1 publication Critical patent/HRP20161566T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/18Drugs for disorders of the endocrine system of the parathyroid hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
HRP20161566TT 2011-06-08 2012-06-08 Terapijski agensi za reguliranje serumskog fosfora HRP20161566T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161494874P 2011-06-08 2011-06-08
PCT/US2012/041759 WO2012170955A1 (en) 2011-06-08 2012-06-08 Therapeutic agents for regulating serum phosphorus
EP12728907.2A EP2717896B1 (en) 2011-06-08 2012-06-08 Therapeutic agents for regulating serum phosphorus

Publications (1)

Publication Number Publication Date
HRP20161566T1 true HRP20161566T1 (hr) 2017-02-24

Family

ID=46321485

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20161566TT HRP20161566T1 (hr) 2011-06-08 2012-06-08 Terapijski agensi za reguliranje serumskog fosfora

Country Status (23)

Country Link
US (1) US8969299B2 (enExample)
EP (1) EP2717896B1 (enExample)
JP (1) JP5982473B2 (enExample)
KR (1) KR102057508B1 (enExample)
CN (1) CN103857405B (enExample)
AU (1) AU2012267470C1 (enExample)
BR (1) BR112013031539A2 (enExample)
CA (1) CA2837445C (enExample)
CY (1) CY1118430T1 (enExample)
DK (1) DK2717896T3 (enExample)
ES (1) ES2607986T3 (enExample)
HR (1) HRP20161566T1 (enExample)
HU (1) HUE032087T2 (enExample)
LT (1) LT2717896T (enExample)
MX (1) MX337613B (enExample)
PL (1) PL2717896T3 (enExample)
PT (1) PT2717896T (enExample)
RS (1) RS55503B1 (enExample)
RU (1) RU2612912C2 (enExample)
SG (1) SG195290A1 (enExample)
SI (1) SI2717896T1 (enExample)
SM (2) SMT201700081T1 (enExample)
WO (1) WO2012170955A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201406921SA (en) 2009-07-29 2014-11-27 Kai Pharmaceuticals Inc Therapeutic agents for reducing parathyroid hormone levels
CN105764487A (zh) 2013-06-28 2016-07-13 美国安进公司 Amg 416(velcalcetide)的稳定的液体制剂
RU2686086C1 (ru) * 2018-05-17 2019-04-24 федеральное государственное бюджетное образовательное учреждение высшего образования "Первый Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова" Министерства здравоохранения Российской Федерации Способ коррекции пресаркопении или саркопении у пациента с адекватным потреблением основных нутриентов, получающего лечение программным гемодиализом
CN114222578B (zh) * 2019-12-09 2024-06-25 北京拓界生物医药科技有限公司 钙敏感受体激动剂化合物及其应用
EP4212542A4 (en) * 2020-09-10 2024-08-28 Shaanxi Micot Technology Co., Ltd. BISPECIFIC FUSION POLYPEPTIDE COMPOUND

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869473A (en) 1988-08-02 1999-02-09 Bone Care International, Inc. Method for treating and preventing hyperparathyroidism
US5602116A (en) 1988-08-02 1997-02-11 Bone Care International, Inc. Method for treating and preventing secondary hyperparathyroidism
US5246925A (en) 1989-03-09 1993-09-21 Wisconsin Alumni Research Foundation 19-nor-vitamin D compounds for use in treating hyperparathyroidism
CA1333616C (en) 1989-03-09 1994-12-20 Hector F. Deluca 19-nor-vitamin d compounds
WO1992008476A1 (en) 1990-11-07 1992-05-29 The Scripps Research Institute Peptides that inhibit platelet binding of adhesion molecules
US6011068A (en) 1991-08-23 2000-01-04 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6031003A (en) 1991-08-23 2000-02-29 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
AU7634694A (en) 1993-08-20 1995-03-21 University Of Medicine And Dentistry Of New Jersey Bridged polycationic polymer-oligonucleotide conjugates and methods for preparing same
CA2145214A1 (en) 1995-02-28 1996-08-29 Rick E. Preddie Agents for pre-symptomatic diagnosis, prevention and cure huntington's disease (hd) in humans
US5688489A (en) 1995-09-15 1997-11-18 Resolution Pharmaceuticals, Inc. Non-receptor mediated imaging agents
US5895368A (en) * 1996-09-23 1999-04-20 Medisystems Technology Corporation Blood set priming method and apparatus
US6165977A (en) 1996-10-18 2000-12-26 Board Of Trustees Of The Leland Stanford Junior University Isozyme-specific activators of protein kinase C methods and compositions
US6258774B1 (en) 1998-03-19 2001-07-10 University Of Medicine And Dentistry Of New Jersey Carrier for in vivo delivery of a therapeutic agent
JP2000336099A (ja) 1999-05-27 2000-12-05 Sekisui Chem Co Ltd ペプチド及びc型肝炎抗体検出用試薬
US6274169B1 (en) 1999-08-02 2001-08-14 Abbott Laboratories Low oxygen content compostions of 1α, 25-dihydroxycholecalciferol
US6051567A (en) 1999-08-02 2000-04-18 Abbott Laboratories Low oxygen content compositions of 1α, 25-dihydroxycholecalciferol
IL153378A0 (en) 2000-07-18 2003-07-06 Bone Care Internat Inc STABILIZED 1alpha-HYDROXY VITAMIN D
US20080249016A1 (en) 2000-09-18 2008-10-09 Sanos Bioscience A/S Use of GLP-2 in a combination treatment for bone-related disorders
US20020168354A1 (en) 2000-11-10 2002-11-14 Daria Mochly-Rosen psiepsilonRack peptide composition and method for protection against tissue damage due to ischemia
EP1351980B1 (en) 2001-01-18 2014-12-31 The Board Of Trustees Of The Leland Stanford Junior University Peptides for activation and inhibition of delta pkc
US20030091640A1 (en) 2001-02-08 2003-05-15 Srinivasan Ramanathan Enhanced oral and transcompartmental delivery of therapeutic or diagnostic agents
US20030036627A1 (en) 2001-02-16 2003-02-20 Montelaro Ronald C. Virus derived antimicrobial peptides
ES2527339T3 (es) 2001-02-23 2015-01-23 Polyphor Ltd. Peptidomiméticos fijados a patrón con actividad antimicrobiana
JP2005287302A (ja) 2002-04-03 2005-10-20 Haruhiko Fujiwara ポリペプチドの架橋方法
EP1576141A4 (en) 2002-05-14 2006-03-22 Bristol Myers Squibb Co NEW HUMAN G-PROTEIN-COUPLED RECEPTORS CODING POLYNUCLEOTIDE AND SPLEISS VARIANTS THEREOF
WO2004093821A2 (en) 2003-04-22 2004-11-04 Hawaii Biotech, Inc. Treatment of anthrax infection using inhibitors of lethal factor protease activity
WO2005049647A2 (en) 2003-11-05 2005-06-02 Pevion Biotech Ltd. Compositions comprising melittin-derved peptides and methods for the potentiation of immune responses against target antigens
WO2005059124A2 (en) 2003-12-11 2005-06-30 The Board Of Trustees Of The Leland Stanford Junior University Isozyme-specific antagonists of protein kinase c
US7939634B2 (en) 2004-01-27 2011-05-10 Compugen Ltd. Polynucleotides encoding polypeptides and methods using same
US7265092B2 (en) 2004-09-30 2007-09-04 Kai Pharmaceuticals, Inc. Pharmaceutical formulation
ITME20040015A1 (it) * 2004-12-07 2005-03-07 Vincenzo Savica Chewing gum, caramelle gommose, pastiglie, compresse a lento rilascio di chelanti fosfato e/o fosforo salivare e capsule a lento rilascio di chelanti fosfato e/o fosforo a livello gastroenterico.
AU2006285127A1 (en) 2005-08-30 2007-03-08 Acologix, Inc. Regulation of mineral and skeletal metabolism
WO2007038172A2 (en) 2005-09-23 2007-04-05 Nitto Denko Corporation Guanidinium carriers
CN103961686A (zh) * 2006-11-16 2014-08-06 凯制药公司 用于治疗甲状旁腺功能亢进和高钙血症的聚阳离子钙调节肽
AU2008206077A1 (en) 2007-01-19 2008-07-24 Kai Pharmaceuticals, Inc. Modifications of peptide compositions to increase stability and delivery efficiency
JP5697450B2 (ja) 2007-10-02 2015-04-08 マリーナ バイオテック,インコーポレイテッド 核酸の送達のためのリポペプチド
WO2009075773A2 (en) 2007-12-07 2009-06-18 Goldstein Steven A Identification of toxin ligands
SG10201406921SA (en) * 2009-07-29 2014-11-27 Kai Pharmaceuticals Inc Therapeutic agents for reducing parathyroid hormone levels

Also Published As

Publication number Publication date
JP2014522414A (ja) 2014-09-04
US8969299B2 (en) 2015-03-03
AU2012267470C1 (en) 2017-09-21
SI2717896T1 (sl) 2017-04-26
KR20140035456A (ko) 2014-03-21
CA2837445C (en) 2022-10-04
HUE032087T2 (en) 2017-08-28
BR112013031539A2 (pt) 2019-07-30
LT2717896T (lt) 2017-02-27
CN103857405A (zh) 2014-06-11
RS55503B1 (sr) 2017-05-31
CN103857405B (zh) 2015-12-02
MX337613B (es) 2016-03-10
PL2717896T3 (pl) 2017-05-31
MX2013014249A (es) 2014-01-24
CA2837445A1 (en) 2012-12-13
WO2012170955A1 (en) 2012-12-13
KR102057508B1 (ko) 2019-12-19
EP2717896A1 (en) 2014-04-16
SG195290A1 (en) 2013-12-30
CY1118430T1 (el) 2017-06-28
PT2717896T (pt) 2016-12-23
SMT201700081B (it) 2017-03-08
EP2717896B1 (en) 2016-08-24
US20130150301A1 (en) 2013-06-13
DK2717896T3 (en) 2016-12-19
JP5982473B2 (ja) 2016-08-31
ES2607986T3 (es) 2017-04-05
AU2012267470B2 (en) 2017-06-15
RU2612912C2 (ru) 2017-03-13
RU2013157928A (ru) 2015-07-20
SMT201700081T1 (it) 2017-03-08

Similar Documents

Publication Publication Date Title
HRP20161566T1 (hr) Terapijski agensi za reguliranje serumskog fosfora
RU2015120804A (ru) Антагонисты активина-actrii и их применение для лечения нарушений костной ткани и других нарушений
BR112015001419A2 (pt) composto, composição farmacêutica, e, métodos para inibir romk em um paciente, para causar diurese, natriurese ou ambos e para tratamento de um ou mais distúrbios
HRP20220225T1 (hr) Terlipresin za liječenje hepatorenalnog sindroma tip 1
BR112015027282A8 (pt) formulação líquida e kit compreendendo fenfluramina, e usos da mesma no tratamento de síndrome de dravet
JP2016520050A5 (enExample)
JP2011126917A5 (enExample)
HRP20230504T1 (hr) Antagonisti aktivin-actrii i upotreba u liječenju mijelodisplastičnog sindroma
JP2015527402A5 (enExample)
MX362597B (es) Sistema y metodo para intercambio de dialisis peritoneal teniendo una unidad energizante reutilizable.
WO2011014255A8 (en) Treatment of crohn's disease with laquinimod
BR112014000380A2 (pt) composição farmacêutica, métodos para tratamento e usos dos mesmos
EA201490377A1 (ru) Лечение рассеянного склероза комбинацией лаквинимода и глатирамера ацетата
SI3004106T1 (en) Dual selective PI3 delta and gamma inhibitors
BR112015025805A2 (pt) compostos de ligação de nh3 e métodos para inibir o transporte de fosfato
HRP20241213T1 (hr) Primjena sepiapterina bez hrane za uporabu u postupku za povećavanje plazmatske izloženosti sepiapterinu
Habas et al. Common complications of hemodialysis: a clinical review
JP2017105859A5 (enExample)
HRP20241584T1 (hr) Postupci liječenja sjögrenovog sindroma inhibitorom brutonove tirozin kinaze
EP4279127A3 (en) Growth differentiation factor 15 as biomarker for metformin
HRP20210891T1 (hr) Liječenje bolesti presatka protiv primatelja u pacijenata s transplantacijom
WO2014110353A8 (en) Notch ligand bound biocompatible substrates and their use in bone formation
JP2010539974A5 (enExample)
JP2009508822A5 (enExample)
FI3634463T3 (fi) Parannettu protokolla lupusnefriitin hoitoon